Pfizer, Inc. (PFE): Price and Financial Metrics

Pfizer, Inc. (PFE): $34.39

0.19 (+0.56%)

POWR Rating

Component Grades













PFE Stock Summary

  • With a market capitalization of $190,754,928,592, Pfizer Inc has a greater market value than 99.15% of US stocks.
  • Pfizer Inc's stock had its IPO on January 1, 1986, making it an older stock than 92.78% of US equities in our set.
  • In terms of volatility of its share price, PFE is more volatile than merely 3.74% of stocks we're observing.
  • Stocks with similar financial metrics, market capitalization, and price volatility to Pfizer Inc are NVS, ABBV, CSCO, LLY, and NVO.
  • Visit PFE's SEC page to see the company's official filings. To visit the company's web site, go to

PFE Stock Price Chart Interactive Chart >

Price chart for PFE

PFE Price/Volume Stats

Current price $34.39 52-week high $43.08
Prev. close $34.20 52-week low $27.88
Day low $33.95 Volume 30,589,900
Day high $34.55 Avg. volume 35,689,750
50-day MA $35.70 Dividend yield 4.54%
200-day MA $36.58 Market Cap 191.81B

Pfizer, Inc. (PFE) Company Bio

Pfizer discovers, develops, manufactures, and sells healthcare products worldwide. The company operates through Global Innovative Pharmaceutical (GIP); Global Vaccines, Oncology and Consumer Healthcare (VOC); and Global Established Pharmaceutical (GEP) segments. Its products include Lyrica, the Prevnar family of products, Enbrel, Celebrex, Lipitor, Viagra, Zyvox, Sutent, EpiPen, Toviaz, Tygacil, Rapamune, Xalkori, Inlyta, Norvasc, BeneFIX, Genotropin, ReFacto, Xyntha and Enbrel, among others. The company was founded in 1849 and is based in New York, New York.

PFE Latest News Stream

Event/Time News Detail
Loading, please wait...

PFE Latest Social Stream

Loading social stream, please wait...

View Full PFE Social Stream

Latest PFE News From Around the Web

Below are the latest news stories about Pfizer Inc that investors may wish to consider to help them evaluate PFE as an investment opportunity.

Scientists skeptical of one-shot regimen for Pfizer, Moderna vaccines - WSJ

U.S. government scientists are pushing back against calls for one-dose regimens for COVID-19 vaccines from Pfizer-BioNTech ([[PFE]], [[BNTX]]) and Moderna (MRNA) designed to be administered with two shots, saying there is not enough evidence that a single dose provides long-term protection, WSJ reports."It is essential that these vaccines be used...

Seeking Alpha | March 7, 2021

Inside the safest place in Ireland that has crushed Covid with vaccines

Sneem was lucky to get the Moderna vaccine as other towns and villages in the region were given the Pfizer vaccine in much smaller supply

Irish Mirror | March 5, 2021 | Rwanda becomes first African nation to use Pfizer COVID-19 vaccine

Rwanda has began its Covid-19 vaccine campaign, becoming the first nation in Africa to use pharmaceutical company doses that require ultra-cold storage.

News24 | March 5, 2021

Johnson & Johnson's COVID-19 Vaccine: Detroit Mayor Declines 6,200 Doses, Catholic Bishops Raise 'Moral Concerns'

The rollout of the Johnson & Johnson (NYSE: JNJ ) COVID-19 vaccine hit a pair of potholes this week as the mayor of Detroit said the city was sticking with Pfizer (NYSE: PFE ) and Moderna (NASDAQ: MRNA ) vaccines for now, highlighting Johnson & Johnson's lower efficacy rate, before walking back his comments. And the nation's Catholic bishops questioned the Johnson & Johnson vaccine's morality because it was created from cell lines derived from an aborted human fetus. Thanks, But No Thanks: Detroit Mayor Mike Duggan declined to accept 6,200 doses of the Johnson & Johnson vaccine this week, and said the new vaccine has lower efficacy rates than the Pfizer (NYSE: PFE ) and Moderna (NASDAQ: MRNA ) vaccines. “The Moderna and Pfizer vaccines are 95% effective if you get two shots,” Duggan sai...

Benzinga | March 5, 2021

Detroit's mayor reportedly said J&J's vaccines aren't as good, so he said declined the city's first shipment

Summary List Placement Detroit's mayor, Mike Duggan, said in a press briefing on Thursday that he would not accept a first-time shipment of Johnson & Johnson's single-shot coronavirus vaccine, CNBC reported on Friday . Duggan reportedly cited concerns about the vaccine's efficacy. The vaccine, according to reporting from Insider, has been proven to be 66% effective at preventing coronavirus overall, and data from Johnson & Johnson shows a 100% prevention rate of hospitalizations from the virus. The FDA approved the Johnson & Johnson vaccine for "emergency use" by Americans over 18 years of age on February 27. "Johnson & Johnson is a very good vaccine," Duggan told media outlets including CNBC on Thursday. "Moderna and Pfizer are the best. And I am going to do everything I can to make su...

Business Insider | March 5, 2021

Read More 'PFE' Stories Here

PFE Price Returns

1-mo -1.52%
3-mo -15.72%
6-mo 3.19%
1-year 7.97%
3-year 11.38%
5-year 49.24%
YTD -5.56%
2020 3.23%
2019 -6.91%
2018 24.82%
2017 15.90%
2016 4.42%

PFE Dividends

Ex-Dividend Date Type Payout Amount Change
Loading, please wait...
View Full PFE Dividend History

Continue Researching PFE

Want to see what other sources are saying about Pfizer Inc's financials and stock price? Try the links below:

Pfizer Inc (PFE) Stock Price | Nasdaq
Pfizer Inc (PFE) Stock Quote, History and News - Yahoo Finance
Pfizer Inc (PFE) Stock Price and Basic Information | MarketWatch

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from!

Page generated in 0.9515 seconds.